Chemcon Speciality Chemicals Limited Stocks

151.36Last Updated 13.04.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 59.38M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
151.36
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chemcon Speciality Chemicals Limited engages in the manufacture and sale of pharmaceutical intermediates, silanes, and oilfield chemicals in India. It offers oilfield chemicals, including calcium bromide liquid, calcium bromide powder, sodium bromide solution, and zinc bromide solution; pharmaceutical chemicals, such as hexamethyl disilazane, chloromethyl isopropyl carbonate, trimethyl chlorosilane, and hexamethyl disiloxane; and Silanes comprising hexamethyl disilazane, trimethyl chlorosilane, and hexamethyl disiloxane, as well as provides contract manufacturing services. The company also exports its products to United States, Italy, South Korea, Germany, the People's Republic of China, Japan, the United Arab Emirates, Serbia, Russia, Spain, Thailand, and Malaysia. The company was incorporated in 1988 and is based in Vadodara, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks